We Can Medicines Co., Ltd. (6929.TWO)
TWD 37.5
(0.0%)
TWD 37.5
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | 139.84 Million | 346.66 Million | 457.15 Million | 79.05 Million |
| Net Income | 21.6 Million | 121.12 Million | 38.79 Million | 42.7 Million |
| Depreciation & Amortization | 276.18 Million | 253.54 Million | 213.76 Million | 197.55 Million |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | 9.97 Million | 4.1 Million | - | - |
| Change in working capital | -181.66 Million | -65.67 Million | 188.47 Million | -174.88 Million |
| Other non-cash items | 18.09 Million | 18.84 Million | 14.37 Million | 13.49 Million |
| Investing Cash Flow | -98.44 Million | -128.44 Million | -345.76 Million | -65.2 Million |
| Investments in PPE | -93.95 Million | -122.91 Million | -342.95 Million | -61.04 Million |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | -5.11 Million | -5.76 Million | -2.86 Million | -4.22 Million |
| Financing Cash Flow | -97.12 Million | -205.32 Million | -28.2 Million | 12.64 Million |
| Debt repayment | -129.78 Million | - | -150 Million | -15 Million |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | - | - | - | 197.21 Million |
| Other Financing Activities | 3.21 Million | 2.18 Million | 1.14 Million | 1 Million |
| Accounts receivables | -93.2 Million | - | - | - |
| Accounts payables | 27.28 Million | - | - | - |
| Inventory | -82.01 Million | -106.48 Million | -54.08 Million | -31.69 Million |
| Other working capital | -6.44 Million | - | - | - |
| Cash at beginning of period | 216.25 Million | 203.36 Million | 120.17 Million | 93.68 Million |
| Cash at end of period | 160.52 Million | 216.25 Million | 203.36 Million | 120.17 Million |
| Capital Expenditure | -93.95 Million | -122.91 Million | -342.95 Million | -61.04 Million |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | -55.73 Million | 12.89 Million | 83.18 Million | 26.48 Million |
| Free Cash Flow | 45.88 Million | 223.74 Million | 114.2 Million | 18 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -6.07 Million | 13.97 Million | 21.6 Million | 7.71 Million | -5.67 Million | -4.57 Million |
| Depreciation & Amortization | 75.79 Million | 74.09 Million | 276.18 Million | 70.93 Million | 70.83 Million | 67.89 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 303 Thousand | 1.71 Million | 9.97 Million | 2.48 Million | 2.5 Million | 2.48 Million |
| Change in working capital | -51.73 Million | -56.45 Million | -181.66 Million | -28.16 Million | -52.39 Million | 35.65 Million |
| Other non-cash items | 2.11 Million | 11.55 Million | 18.09 Million | 1.64 Million | 5.61 Million | 5.55 Million |
| Investing Cash Flow | -16.98 Million | -24.11 Million | -98.44 Million | -23.34 Million | -22 Million | -23.17 Million |
| Investments in PPE | -17.87 Million | -23.3 Million | -93.95 Million | -22.64 Million | -20.24 Million | -23.62 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 417 Thousand | -889 Thousand | -5.11 Million | -967 Thousand | -1.81 Million | 214 Thousand |
| Financing Cash Flow | -208.5 Million | 284.28 Million | -97.12 Million | -20.66 Million | 35.12 Million | -152.23 Million |
| Debt repayment | -146.74 Million | -8.24 Million | -129.78 Million | -38.25 Million | -93.26 Million | -96.73 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 338.85 Million | - | - | - | - |
| Other Financing Activities | 1.21 Million | -458 Thousand | 3.21 Million | 1.07 Million | 394 Thousand | 986 Thousand |
| Accounts receivables | 3.35 Million | - | - | - | - | - |
| Accounts payables | 28.85 Million | - | - | - | - | - |
| Inventory | -42.42 Million | -49.74 Million | -82.01 Million | -2.6 Million | -7.88 Million | -10.02 Million |
| Other working capital | -42.39 Million | - | - | - | - | - |
| Cash at beginning of period | 465.45 Million | 160.52 Million | 216.25 Million | 149.27 Million | 115.84 Million | 188.66 Million |
| Cash at end of period | 256.41 Million | 465.45 Million | 160.52 Million | 160.52 Million | 149.27 Million | 115.84 Million |
| Capital Expenditure | -17.87 Million | -23.3 Million | -93.95 Million | -22.64 Million | -20.24 Million | -23.62 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -209.04 Million | 304.92 Million | -55.73 Million | 11.25 Million | 33.42 Million | -72.81 Million |
| Free Cash Flow | -1.42 Million | 21.45 Million | 45.88 Million | 32.61 Million | 62 Thousand | 78.96 Million |
CZFS
SEBC
VIRINCHI
ASAZF
UNCFF
8513